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Assessment of intermediate coronary lesions (30--70% stenosis) by coronary angiogram has been shown to be a poor predictor of the hemodynamic significance of the lesion \[[@CR1]\]. Earlier studies had suggested that fractional flow reserve (FFR)-guided revascularization was superior at reducing major cardiac adverse outcomes when compared with angiogram-guided revascularization \[[@CR2]--[@CR4]\]. The 5-year follow-up of the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME; Clinicaltrials.gov identifier, NCT00267774) trial demonstrated that an FFR-guided approach is associated with a similar risk of major events but with a lower number of stented arteries and less resource use \[[@CR5]\]. FFR assessment during coronary angiography is endorsed by the European Society of Cardiology and the American College of Cardiology for identification of hemodynamically significant lesions when non-invasive evidence of myocardial ischemia is unavailable \[[@CR6], [@CR7]\]. Deferral of revascularization is recommended for non-ischemic lesions \[[@CR8], [@CR9]\]. Despite the documented benefits of FFR, some operators may not embrace the frequent use of FFR. This might be especially true in a fee-for-service system, where FFR could result in deferral of revascularization. The Veterans Health System is unique in that there is no financial incentive to perform revascularization procedures. Therefore, at a single-center Veterans Administration Hospital, our objectives were twofold. The first objective was to determine how frequently FFR was performed. The second objective was to determine how FFR values would impact the performance or deferral of revascularization, especially within the gray zone.
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This was a single-center study that prospectively entered all patients referred for cardiac catheterization for any indication at the North Florida/South Georgia Veterans Health System from May 2012 until January 2014 into a database. This database was established to determine the frequency of FFR usage and how FFR values impact revascularization decisions; therefore, baseline characteristics and clinical outcomes were not recorded. Institutional Review Board approval was obtained prior to conducting the study. FFR was defined as a whole cardiac cycle pressure-derived index of the maximum achievable blood flow in a coronary artery with a stenosis expressed as a ratio of maximum achievable blood flow if that artery were normal \[[@CR8], [@CR10]\]. FFR was measured in all intermediate coronary lesions (30--70% stenosis) using a coronary pressure guide wire (Volcano Corporation; San Diego, CA) at maximal hyperemia induced by peripherally administrated intravenous adenosine (140 µg/kg/min for 2 min) or regadenoson (0.4 mg bolus) at operator discretion. Based on the FFR results, the lesions were categorized into three different groups: FFR \> 0.80 (non-ischemic), FFR 0.75--0.80 (gray zone), and FFR \< 0.75 (ischemic). The decision to defer or proceed with revascularization on the basis of FFR measurement was left to the operator's judgment.
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A total of 1482 cardiac catheterizations were performed during the study period. FFR was performed in 347 (23%) of these procedures. The total numbers of intermediate coronary lesions evaluated with FFR were 429. The mean FFR value was 0.79 (median = 0.80, interquartile range 0.64--0.96). Among 211 non-ischemic lesions, revascularization was deferred in 201 (95%). In the remainder of patients with non-ischemic lesions, referral was placed for coronary artery bypass grafting surgery (CABG) for concomitant lesions in eight patients and percutaneous coronary intervention (PCI) was performed in two cases due to intravascular ultrasound findings. In the gray-zone group (73 lesions), 35 (48%) lesions were treated with PCI, 11 (15%) lesions were referred for CABG, and 27 (37%) lesions were treated medically. In the ischemic group (145 lesions), 82 (57%) lesions were treated with PCI, 41 (28%) lesions were referred for CABG, and 22 (15%) lesions were treated medically. In the gray-zone group, the most common reasons for deferring revascularization included mild angina symptoms, inadequate anti-angina therapy, or high PCI complexity. In the ischemic group, the most common reasons for deferring revascularization included small vessel size (i.e., \<2.25 mm) and/or diffuse lesions that markedly increased the risk for restenosis, or high PCI complexity. Figure [1](#Fig1){ref-type="fig"} summarizes the percentage of lesions in each group.Fig. 1Summary for the percentage of lesions in each group. **a** Percentage of lesions in each fractional flow reserve category. Distribution of treatment (medical, revascularization, or referral for CABG) in the non-ischemic group (**b**), gray-zone group (**c**), and ischemic group (**d**). *CABG* coronary artery bypass grafting surgery, *PCI* percutaneous coronary intervention
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In the United States, the average use of FFR has been reported to be as low as 6.1%, with more FFR procedures performed in academic institutions, particularly those with fellowship programs \[[@CR11]\]. FFR usage is affected by operator expertise, reimbursement, and the availability of necessary equipment. At our institution, FFR was performed at a higher rate than previously reported; however, as previously mentioned, the Veterans Health System is unique since there is no financial incentive to perform revascularization procedures. Incorporating FFR in revascularization decisions has been demonstrated to result in fewer PCI procedures \[[@CR2], [@CR12]--[@CR14]\]. Our results showed that FFR usage resulted in deferral of revascularization in approximately half of the cases due to non-ischemic lesions.

In the gray-zone group, approximately 63% of the lesions either underwent PCI or referred for CABG, which is slightly higher than prior studies \[[@CR15], [@CR16]\]. Recent studies had suggested increasing the sensitivity for detecting ischemia (i.e., the threshold for revascularization changed from FFR \< 0.75 to \<0.80) \[[@CR4]\]. We observed that 37% of gray-zone lesions were deferred revascularization which illustrates that in real-life clinical practice there is still adequate room for medical management and clinical judgment for such lesions. In other words, an FFR value \<0.80 should not be an 'automatic license' to perform revascularization. Revascularization was deferred in the gray-zone group mostly due to mild symptoms and/or inadequate anti-angina therapy. In the ischemic group, revascularization was deferred infrequently (15%). This was mostly due to anatomical concerns (characteristics that made PCI high risk or significantly increased the risk for restenosis).

This study was limited by being an observational study conducted in a single academic center. We did not report any baseline characteristics or clinical outcome data; however, this information would not be considered particularly germane to the stated objectives of this study. Moreover, this information can be found in other reports. Meta-analysis of observational studies has documented similar outcomes associated with deferral of non-ischemic left main lesions compared with revascularization of ischemic left main lesions. On the other hand, adverse outcomes are low with deferral of non-ischemic lesions compared with revascularization of ischemic lesions for non-left main lesions \[[@CR9]\].

Conclusions {#Sec5}
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In a single-center practice that does not provide a financial incentive for performing revascularization procedures, FFR usage occurred at a higher frequency than previously reported (approximately one in four catheterization procedures). Frequent use of FFR documented lack of ischemia in about half of the intermediate coronary lesions, and thus reduced the need for many revascularization procedures.
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